Gemcitabine: In Combination with Carboplatin in the Treatment of Recurrent Ovarian Cancer

ISSN： 1175-6357

Source： American Journal of Cancer, Vol.4, Iss.5, 2005-01, pp. : 337-344

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

utrif Gemcitabine has well established antitumor activity against a variety of solid tumors, including ovarian cancer, and hematologic malignancies. It has recently been approved in several European countries for use with carboplatin for the treatment of advanced ovarian cancer in patients with recurrent disease 6 months after platinum-based, first-line therapy. utrif Gemcitabine plus carboplatin chemotherapy significantly increased progression-free survival compared with carboplatin alone in a randomized study in women with advanced, platinum-sensitive, recurrent, ovarian cancer. utrif Significantly more gemcitabine plus carboplatin recipients achieved an overall (complete or partial) response to treatment than patients who received carboplatin only in the randomized trial. In two noncomparative trials, up to 63% of gemcitabine plus carboplatin recipients achieved an overall response to treatment. utrif The most frequently occurring adverse events with gemcitabine were those related to noncumulative myelosuppression. Hematologic toxicities were significantly higher with gemcitabine plus carboplatin than with carboplatin alone. Nonhematologic adverse events were generally mild to moderate in severity.